SCAPE — Sympathetic Crashing Acute Pulmonary Edema

SCAPE — Sympathetic Crashing Acute Pulmonary Edema

What is SCAPE?

SCAPE = Sympathetic Crashing Acute Pulmonary Edema

It represents the extreme end of the acute heart-failure/pulmonary-edema spectrum, characterized by:

• abrupt onset severe dyspnea
• severe respiratory distress
• marked sympathetic activation
• usually severe hypertension
• tachycardia
• diaphoresis
• agitation/anxiety
• hypoxemia
• diffuse pulmonary edema
• very rapid clinical deterioration

The patient may progress from being awake and hypertensive to respiratory arrest and intubation within minutes if treatment is delayed.

Importantly, SCAPE is a clinical phenotype, not simply “any pulmonary edema with high BP.”

Clinical Features

A patient who suddenly wakes up gasping for air, is sitting upright, drenched in sweat, extremely hypertensive, tachycardic, hypoxemic and has bilateral crackles.

Typical presentation:

Research definitions have commonly used acute dyspnea, SBP ≥160 mmHg and/or DBP ≥100 mmHg/MAP ≥120 mmHg, RR ≥30, hypoxemia and sympathetic features, although there is no universally accepted diagnostic threshold. 

Pathophysiology

Step 1 — Trigger

SCAPE may be triggered by:

• acute hypertension
• myocardial ischemia
• acute LV dysfunction
• acute coronary syndrome
• renal disease
• medication non-adherence
• dietary salt excess
• arrhythmia
• acute valvular disease
• renal artery disease
• sympathetic activation
• withdrawal of antihypertensive therapy
• acute aortic pathology
• pheochromocytoma
• catecholamine excess

Sometimes no obvious trigger is immediately identified.

Sympathetic surge

A sudden rise in sympathetic activity causes:α₁-mediated vasoconstriction→ systemic vascular resistance ↑

Venoconstriction

→ venous capacitance decreases

→ blood is shifted centrally

β₁ stimulation

→ heart rate ↑

→ contractility ↑

→ myocardial oxygen demand ↑

This creates a vicious cycle.

The central problem: afterload

The most important pathophysiological abnormality in SCAPE is often:Sudden, severe increase in LV afterload.

The LV suddenly has to eject against a very high systemic vascular resistance.Consequences:

SVR ↑

↓

LV wall stress ↑

↓

LV ejection becomes difficult

↓

Stroke volume may fall

↓

LV end-diastolic pressure ↑

↓

Left atrial pressure ↑

↓

Pulmonary capillary hydrostatic pressure ↑

↓

Interstitial pulmonary edema

↓

Alveolar edema

↓

Severe hypoxemia

↓

More sympathetic activation

↓

Further vasoconstriction

↓

Even more pulmonary edema

This is the SCAPE vicious cycle.

Why pulmonary edema develops so quickly

The important concept is:

Redistribution rather than accumulation.

The sympathetic surge causes blood to shift from the systemic venous/splanchnic circulation toward the central circulation.

At the same time:

• systemic vascular resistance rises
• LV afterload rises
• LV filling pressure rises
• pulmonary capillary hydrostatic pressure rises

Therefore pulmonary edema can appear within minutes.

This explains the term “flash pulmonary edema.”

Evaluation

History

Cardiac

• Previous HF?
• Previous pulmonary edema?
• CAD?
• MI?
• Hypertension?
• Cardiomyopathy?
• Valvular disease?
• AF?
• Arrhythmia?

Medication

• Missed antihypertensives?
• Missed diuretics?
• NSAIDs?
• Steroids?
• Recent medication change?

Renal

• CKD?
• Dialysis?
• Missed dialysis?
• Reduced urine output?

Ischemia

• Chest pain?
• Anginal equivalent?
• Diaphoresis?

Precipitants

• Infection?
• Arrhythmia?
• ACS?
• Hypertensive crisis?
• Acute valvular lesion?
• Renal failure?
• Drug use?

Examination Look for:

Respiratory

• RR
• SpO₂
• accessory muscle use
• inability to speak
• crackles
• frothy sputum
• cyanosis

Cardiovascular

• BP
• HR
• JVP
• peripheral edema
• S3
• murmurs
• signs of acute MR/AR

Sympathetic activation

• diaphoresis
• agitation
• anxiety
• tachycardia
• cold extremities

POCUS in SCAPE

Lung ultrasound

Typical:Diffuse bilateral B-lines

with:

• bilateral distribution
• relatively symmetric pattern
• pleural sliding usually preserved

B-lines indicate increased extravascular lung water but are not specific for cardiogenic edema.

Cardiac POCUS

Look for:

• LV systolic function
• RV size/function
• pericardial effusion
• regional wall-motion abnormality
• severe valvular pathology
• LV hypertrophy
• gross volume status
• IVC

However:A normal or hyperdynamic LV does NOT exclude SCAPE.

Especially in hypertensive HFpEF physiology.

IVC

IVC assessment can be supportive but should not determine whether the patient has SCAPE.

A patient can have:

• pulmonary edema
• high LV filling pressure
• severe hypertension

without obvious IVC plethora.

And positive-pressure ventilation changes IVC physiology.

Therefore:

Do not use IVC alone to decide whether SCAPE is present or whether diuretics are needed.

ECG

Obtain immediately.

Look for:

• STEMI
• NSTEMI changes
• ischemia
• LVH
• AF
• SVT
• bradyarrhythmia
• ventricular arrhythmia

ECG should occur concurrently with treatment, not delay treatment.

Chest X-ray

Possible findings:

• bilateral alveolar infiltrates
• perihilar “bat-wing” pattern
• interstitial edema
• Kerley B lines
• cardiomegaly
• pleural effusion

But:Do not wait for CXR before starting SCAPE treatment.

Laboratory evaluation

Depending on clinical context:

• ABG/VBG
• electrolytes
• creatinine
• glucose
• CBC
• troponin
• BNP/NT-proBNP
• lactate
• LFT
• magnesium
• coagulation profile if indicated

The laboratory workup should identify precipitating pathology, not delay resuscitation.

ABG pattern

May show:

Early

• hypoxemia
• respiratory alkalosis

Severe/prolonged

• respiratory acidosis
• hypercapnia
• mixed acidosis
• rising lactate

Hypercapnia is particularly concerning because it may indicate respiratory muscle fatigue and impending ventilatory failure.

SCAPE vs volume-overload acute HF

Management

The two pillars of SCAPE treatment

1. Non-invasive positive-pressure ventilation(CPAP/BIPAP)

2. Rapid vasodilation with nitrates

Why NIPPV works

NIPPV provides several beneficial effects.

A. Improves oxygenation

B. Reduces work of breathing

C. Reduces venous return

Positive intrathoracic pressure →

venous return ↓

↓

RV preload ↓

↓

pulmonary blood flow may decrease.

D. Reduces LV afterload

Positive intrathoracic pressure can reduce LV transmural pressure.

Therefore:

NIPPV is not merely an oxygenation treatment—it has favorable cardiovascular effects.

The pharmacological cornerstone: nitroglycerin

Nitroglycerin is particularly useful because it produces:

Venodilation→ preload reduction

AND at sufficiently high doses:Arteriolar dilation→ afterload reduction.

The second effect is particularly important in SCAPE.

Why conventional low-dose nitroglycerin may be inadequate

Traditional nitroglycerin dosing often starts around:5–20 μg/min

and is gradually titrated.

At lower doses:venodilation predominates.

But SCAPE is often driven by:massive vasoconstriction + severe afterload elevation.

Therefore, very low doses may not sufficiently reverse the pathophysiology.High-dose nitroglycerin

Step 1. Initial loading dose

• IV nitroglycerin bolus: 1,000–2,000 mcg (1–2 mg) over approximately 2 minutes, in selected patients with severe hypertensive SCAPE under continuous monitoring.
• An alternative described in SCAPE protocols is an infusion at 400–800 mcg/min for approximately 2.5 minutes.
• These are high-dose, protocol-specific strategies, not routine nitroglycerin dosing. Use only with appropriate expertise, reliable IV access, and frequent or continuous BP assessment.

Main risk: Hypotension, particularly with occult hypovolemia or preload-dependent physiology. Stop or reduce the dose if hypotension develops.

Step 2. Maintenance infusion

• Starting rate: 100–300 mcg/min in high-dose SCAPE protocols.
• Titrate rapidly according to BP, respiratory distress, and clinical response. Selected patients may require doses up to approximately 800 mcg/min in specialist protocols.
  

Sublingual nitroglycerin when IV treatment is unavailable

• May be used as a temporary bridge while arranging immediate transfer to a monitored setting for IV therapy and NIV.
• Some SCAPE protocols describe 400-mcg tablets, 3–5 tablets every 5 minutes. However, this is an aggressive, protocol-specific approach with limited evidence; it should not be treated as a universal dosing recommendation

What is the target BP?

There is no universally validated exact target.

Rapid but controlled reduction in BP while maintaining adequate organ perfusion.

A reasonable initial target in severely hypertensive SCAPE is often:

SBP ~140 mmHg rather than immediately normalizing BP.

Avoid:abrupt excessive hypotension.

The patient needs enough arterial pressure to maintain:

• coronary perfusion
• cerebral perfusion
• renal perfusion.

Contraindications/major cautions to nitrates

Avoid or use extreme caution with:

Absolute/major situations

• significant hypotension
• shock
• recent PDE-5 inhibitor use
• severe RV preload dependence
• severe aortic stenosis depending on clinical circumstances
• marked hypovolemia

PDE-5 inhibitors are especially important:

• sildenafil
• tadalafil
• vardenafil
• avanafil

because profound hypotension can occur with nitrates.

Why diuretics are NOT the first treatment

This is one of the most important SCAPE exam concepts.

Traditional management:

pulmonary edema → furosemide.

But in SCAPE, the dominant problem may be:

redistribution + afterload excess rather than absolute volume excess.

IV loop diuretics have:

• slower onset of meaningful decongestive effect
• delayed natriuresis
• potential worsening of intravascular depletion

Therefore:

Do not delay NIPPV and nitrates while waiting for furosemide.

Modern SCAPE reviews specifically discourage routine immediate diuretic therapy when systemic volume overload is not evident. 

Diuretics are not  completely contraindicated?

This distinction is extremely important.

If the patient has genuine systemic volume overload:

• peripheral edema
• elevated JVP
• weight gain
• chronic congestion
• cardiomegaly
• significant venous congestion
• missed dialysis
• obvious fluid excess

then loop diuretics are appropriate.

Therefore:Diuretics are phenotype-dependent, not forbidden.

What about beta-blockers?

• Acute beta-blockade can worsen hemodynamics by impair pump function.Therefore:Do not reflexively give beta-blockers simply because the patient is tachycardic/hypertensive.Treat the underlying sympathetic crisis and afterload first.Beta-blockers may have a role in specific situations once hemodynamics are stabilized or for a specific precipitant.

What if hypertension persists despite NTG?

If the patient remains severely hypertensive despite:

• Maximise NIPPV (can go upto 20cm)
• appropriately titrated high-dose NTG

consider additional IV antihypertensive therapy.

Potential agents include:

• Nicardipine 
• Clevidipine(preferred due to its shorter half-life )
• Nitroprusside (limitation is cyanide or thiocyanate accumulation)

Important distinction: SCAPE is not synonymous with hypertensive emergency

Most SCAPE patients are markedly hypertensive.

But the essential phenotype is:acute pulmonary edema with sympathetic activation and rapid deterioration.

A patient with acute pulmonary edema and normal/low BP may have another phenotype such as:

• cardiogenic shock
• acute MI
• severe LV dysfunction
• myocarditis
• acute MR
• arrhythmia.

In those patients:Do NOT blindly apply aggressive nitrate therapy.

What NOT to do

❌ Do not wait for CXR

Treatment should begin clinically.

❌ Do not start with low-flow oxygen alone in severe distress

Use NIPPV early.

❌ Do not reflexively give furosemide first

Assess volume phenotype.

❌ Do not routinely give morphine

Potential harm.

❌ Do not reflexively beta-block severe tachycardia

May worsen acute LV failure.

❌ Do not give liters of fluid because BP falls slightly

Assess physiology.

❌ Do not delay intubation when NIV is failing

Airway safety comes first.